ArticleBMC medical imaging2026
Vascular ultrasound-based risk stratification model for atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aimed to investigate the ability of an ultrasound-based risk stratification model integrating carotid intima thickness (CIT) and carotid-femoral pulse wave velocity (cfPWV) to aid in risk stratification and assessment of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM), thereby providing an objective basis for identifying high-risk individuals and informing individualized management strategies.
methodsA total of 105 patients with T2DM were enrolled in this study. According to the 10-year ASCVD risk score, patients were further classified into T2DM patients with low-to-moderate burden of other cardiovascular risk factors and T2DM patients with high burden of other cardiovascular risk factors. CIT was measured using high-resolution ultrasound to assess vascular structure, while cfPWV was evaluated using the automatic measurement of arterial stiffness (AMAS) system to assess vascular function. Logistic regression and least absolute shrinkage and selection operator (LASSO) regression analyses were performed to identify independent risk factors of high ASCVD risk. Based on these risk factors, individual discriminative models and a nomogram were constructed. Receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were used to evaluate model performance, and differences among models were assessed using the DeLong test.
resultsCIT, cfPWV, and estimated glomerular filtration rate (eGFR) were identified as independent risk factors of high 10-year ASCVD risk in patients with T2DM. The areas under the curve (AUCs) for the CIT model, cfPWV model, eGFR model, combined CIT-cfPWV model, and the nomogram were approximately 0.781, 0.808, 0.797, 0.831, and 0.875, respectively. The constructed nomogram demonstrated excellent discrimination, calibration, and clinical applicability.
conclusionsCIT and cfPWV show strong potential for identifying T2DM patients at high ASCVD risk as estimated by the China-PAR model. Incorporating these parameters into vascular evaluation may aid in risk stratification and provide a robust basis for individualized clinical intervention strategies. Prospective studies are needed to validate their prognostic value for future ASCVD events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.